Strategic Analysis of the Global Breast Cancer Therapeutics Pipeline


USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

This research service includes many aspects of the pipeline analysis for the breast cancer therapeutics market including: drivers, restraints, existing market trends, pipeline trends, challenges, biotech out-licensing trends and strategies, strategic company profiles, financial analysis and awards.

Table of Contents

Strategic Analysis of the Global Breast Cancer Therapeutics PipelineOverviewIntroductionDisclaimerCertificationSummaryOutline SlideSummary of FindingsSummary of Findings by SegmentResearch Scope and MethodologyCompetitive FrameworkTechnology Evolution TrajectoryPotential ThreatsStrategic AnalysisOutline SlideMarket SegmentationMarket DriversMarket RestraintsIndustry ChallengesExisting CompaniesExisting ProductsCompetitive LandscapeOutline SlidePipeline Therapeutic TrendsValue of Biotech Out-License DealsAverage Size of Biotech Out-License DealsAverage Size of Biotech Out-License Deals by Payment ClassAverage Size of Biotech Out-License Deals by StageU.S. Drug Approval ProcessPhase I Pipeline AnalysisOutline SlideClinical Development SlideR1550 (Antisoma)Panzem (EntreMed)CEA-Cide (Immunomedics)Executive Quote (Immunomedics)HER-2/neu Vaccine (Corixa)BrevaRex (AltaRex)Phase II Pipeline Analysis AOutline SlideClinical Development SlideAPC8024 (Dendreon)Executive Quote (Dendreon)Advexin (Introgen)Iressa (AstraZeneca)Zarnestra (Johnson & Johnson)Telcyta (Telik)TriAb (Titan Pharmaceuticals)INGN 225 (Introgen)Xyotax (Cell Therapeutics)BMS-275291 (Bristol-Myers Squibb)ERA-923 (Wyeth)Phase II Pipeline Analysis BOmnitarg (Genentech)CI-1033 (Pfizer)CCI-779 (Wyeth)LEP/LED (NeoPharm)Alimta (Lilly)Genasense (Genta)Phase III Pipeline Analysis AOutline SlideClinical Development SlideEnhanzyn (Corixa)Avastin (Genentech)Doxil (Alza)Arzoxifene (Eli Lilly)GW-572016 (GlaxoSmithKline)Atamestane (BioMedicines)Tavocept (BioNumerik)Evista (Eli Lilly)Gemzar (Eli Lilly)Herceptin (Genentech)Phase III Pipeline Analysis BLasofoxifene (Pfizer)Navelbine (GlaxoSmithKline)Theratope (Biomira)Executive Quote (Biomira)109881-Taxoid (Aventis)Celebrex (Pfizer)Xeloda (Roche)Tesmilifene (YM Biosciences)Executive Quote (YM Biosciences)Company AnalysisOutline SlideAltaRex and AlzaAntisoma and AstraZenecaAventis and BioMedicinesBioMira and BioNumerikBristol-Myers Squibb and CellTechCell Therapeutics and CorixaDendreon and EntreMedGenentech and GentaGlaxoSmithKline and ImmunomedicsIntrogen Therapeutics and Johnson & JohnsonLigand Pharmaceuticals and Eli LillyNeoPharm and PfizerRoche and TelikTitan Pharmaceuticals and WyethYM BiosciencesDecision Support DatabasesOutline SlideBreast Cancer Incidence ABreast Cancer Incidence BBiotechnology Companies ABiotechnology Companies BPharmaceutical R&D Expenditure APharmaceutical R&D Expenditure BFrost & Sullivan AwardsOutline SlideIntroduction to Frost & Sullivan AwardsGrowth Strategy of the Year AwardInnovative Technology Leadership of the Year AwardBusiness Development Strategy Leadership of the Year AwardBiotechnology Emerging Company of the Year AwardFrost & SullivanOutline SlideHealthcare TeamOur CapabilitiesKey AdvantagesOur Consulting ClientsFrost & Sullivan Growth ConsultingGrowth Consulting ProcessGrowth Consulting DeliverablesGrowth Partnership ServicesGrowth Partnership Service Platform

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.